Hims & Hers Health, Inc. (NYSE: HIMS ) leads the fast-growing health and wellness market using its technology-based platform to offer personalized, accessible care. The company has been a pioneer in subscription-based healthcare, driving substantial revenue and subscriberYiannis Zourmpanos, founder of Yiazou IQ, an AI-driven stock research platform providing all-in-one stock reports. Experience: Previously worked at Deloitte and KPMG in external/internal auditing and consulting. Education: Chartered Certifi ...

Shares of Hims & Hers were on fire Monday because the FDA's new leader seems to be a fan of the company's business model.Shares of Hims & Hers (HIMS 0.61%) jumped as much as 23% in trading on Monday after President Trump announced his new Food and Drug Administration (FDA) chief, who happens to have ties to a business similar to Hims & Hers. In this video, Travis Hoium covers why this is important and why the stock is moving as fast as it is.*Stock prices used were end-of-day prices of Nov. 25, 2024. The vi ...

Schaeffer's Weekend Trader subscribers scored a big win just in time for Thanksgiving. Bulls doubled their money with our Hims & Hers Health Inc (NYSE:HIMS) February 17 call recommendation in just over one week, so now is a good time to see how the trade played out. At the time of our recommendation on Nov. 17, HIMS had just nabbed an all-time high after a push above $30, which was three times its 2019 initial public offering (IPO) price. A sharp pullback followed that peak, which may have been exaggerated ...

Telehealth stock Hims & Hers Health Inc (NYSE:HIMS) nabbed an all-time high last week after a push above $30, which happens to be three times its 2019 initial public offering (IPO) price. The peak was followed by a sharp pullback, which may have been exaggerated by an unwinding of long positions associated with expiring November call open interest (OI) and delta-hedge selling related to heavy out-of-the-money OI in 11/22 through standard December options. There is plenty of support lingering below to captur ...

Is the food business the right business for Hims & Hers to be in?Hims & Hers (HIMS 0.79%) announced this week that it's getting into the nutrition business with bars and shakes. But are these the right products to add to a pharmaceutical business? Travis Hoium breaks down the news and how this fits into Hims & Hers' business in this video.*Stock prices used were end-of-day prices of Nov. 21, 2024. The video was published on Nov. 21, 2024. ...

INDIA - 2024/11/06: In this photo illustration, a HIMS logo seen displayed on a smartphone and in ... [+] the background. (Photo Illustration by Avishek Das/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty Images The stock price of Hims & Hers Health (NYSE: HIMS), a telehealth platform, has risen a solid 14% in a week. Much of this move came after the U.S. FDA asked for more time to confirm the shortage of Eli Lilly’s weight loss drug – Zepbound. The shortage of GLP-1 drugs bodes w ...

Investment Rating - The report assigns a positive investment rating to HIMS & HERS HEALTH (HIMS.US) based on strong demand for personalized medical solutions and the company's growth potential in the weight management sector [2]. Core Insights - The company reported a revenue of $401.6 million for the third quarter of fiscal year 2024, representing a year-over-year increase of 77%. Online revenue accounted for 97.8% of total revenue, growing by 79% year-over-year [2]. - The gross margin for the quarter was 79.16%, a decrease of 2 percentage points quarter-over-quarter, primarily due to the early stages of scaling the weight management business. Operating profit margin was 5.57%, with operating profit of $220,000, largely driven by marketing expenses, which accounted for 45% of total revenue [2]. - The total number of subscription users exceeded 200,000, a year-over-year increase of 44%. Average monthly revenue per online user grew by 24% to $67, with nearly 300,000 subscribers receiving treatment for two or more conditions [2]. Summary by Sections Financial Performance - For the third quarter, the company achieved a net profit of $75.6 million and free cash flow of $79.4 million [2]. - The company plans to launch a generic version of liraglutide, a GLP-1 weight loss drug, in 2025, addressing the current shortage and difficulties in accessing branded weight loss solutions [2]. Market Dynamics - The demand for personalized medical solutions is strong, with personalized subscription users surpassing 1.03 million, a year-over-year increase of 175% and a quarter-over-quarter increase of 32%, representing 50.5% of total subscription users [2]. - Four main factors are driving the rapid adoption of personalized solutions: detailed service offerings, increased number of cross-specialty solutions, more medication delivery options, and improved affordability of solutions [2].

Hims & Hers has given back recent gains, but don't overlook the company's massive growth.Shares of Hims & Hers (HIMS -7.34%) is down big this week after Amazon (AMZN -4.19%) announced its expansion into telehealth. The market thinks this is terrible news, but is it? Travis Hoium covers the industry dynamics in this video.*Stock prices used were end-of-day prices of Nov. 14, 2024. The video was published on Nov. 14, 2024. ...

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool. ...

Hims & Hers (NYSE: HIMS ) has attracted much investor interest this year due to its accelerating revenue growth and rapidly improving profitability. The stock soared 134% up until November 14, compared to the S&P 500's ( I have been a Merchant Seaman that has traveled the world for over 30 years. Within the last 15 years, I developed a very intense interest in investing. I learned a lot of what I know about investing from The MF. Also because I have a engineering background, I often tend to gravitate to Tec ...